Related Experiment Videos

[Effect of urinastatin on disseminated intravascular coagulation]

Insights

Urinastatin (MTI) effectively treats disseminated intravascular coagulation (DIC) by normalizing clotting times and fibrin degradation products. This urinary enzyme inhibitor shows promise in preventing DIC progression in both animal models.

Area of Science:

  • Biochemistry
  • Hematology
  • Pharmacology

Background:

  • Disseminated intravascular coagulation (DIC) is a life-threatening condition characterized by systemic activation of coagulation.
  • Current treatments for DIC aim to manage coagulation and support organ function, but novel therapeutic strategies are needed.

Purpose of the Study:

  • To investigate the therapeutic effect of urinastatin (MTI), a urinary enzyme inhibitor, on endotoxin-induced disseminated intravascular coagulation (DIC).

Main Methods:

  • The study utilized animal models of DIC induced by endotoxin in rats and rabbits.
  • Intravenous infusion of MTI was administered to rats, and its effects on coagulation parameters were assessed.
  • In vitro experiments involved adding MTI to whole blood from rabbits with DIC to evaluate its impact on thromboelastography.

Main Results:

  • MTI infusion restored prolonged partial thromboplastin time (PTT) and increased fibrin degradation products (FDP) in endotoxin-induced DIC in rats.
  • MTI partially suppressed the reduction in platelet counts, decrease in fibrinogen levels, and prolongation of prothrombin time (PT).
  • In vitro, MTI prevented detrimental changes in thromboelastogram values (r, k, ma, m epsilon) in endotoxin-induced DIC.

Conclusions:

  • Urinastatin (MTI) demonstrates significant efficacy in mitigating DIC in vivo and in vitro.
  • MTI may exert its protective effects by inhibiting Factor XII activity and preventing endotoxin-induced thromboplastin release.

Related Concept Videos